Salazar-Valdivia Farley E, Valdez-Cornejo Valeria A, Ulloque-Badaracco Juan R, Hernandez-Bustamante Enrique A, Alarcón-Braga Esteban A, Mosquera-Rojas Melany D, Garrido-Matta Diana P, Herrera-Añazco Percy, Benites-Zapata Vicente A, Hernandez Adrian V
Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.
Sociedad Científica de Estudiantes de Medicina de la Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.
Diagnostics (Basel). 2023 Feb 22;13(5):843. doi: 10.3390/diagnostics13050843.
The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3-8.9; < 0.001; I = 78) and PFS (HR = 3.9; 95% CI 2.53-6.02; < 0.001; I = 0). No indication of small study effects was found in the association between SIII values and OS ( = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.
全身免疫炎症指数（SIII）是在多种类型的泌尿生殖系统癌症中进行研究的一个标志物。本系统评价评估了SIII值与睾丸癌患者总生存期（OS）和无进展生存期（PFS）之间的关联。我们在五个数据库中检索了观察性研究。采用随机效应模型进行定量合成。使用纽卡斯尔-渥太华量表（NOS）评估偏倚风险。唯一的效应量度是风险比（HR）。根据研究中的偏倚风险进行了敏感性分析。共有6个队列，833名参与者。我们发现，高SIII值与较差的OS（HR = 3.28；95%CI 1.3 - 8.9；P < 0.001；I² = 78）和PFS（HR = 3.9；95%CI 2.53 - 6.02；P < 0.001；I² = 0）相关。在SIII值与OS之间的关联中未发现小研究效应的迹象（P = 0.5301）。高SIII值与较差的OS和PFS相关。然而，建议进一步开展原始研究以增强该标志物在睾丸癌患者不同结局中的作用。
